Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.

Also called NCT02027753

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 109 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02027753
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02027753. Allocation not applicable; no masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy
Acronym
TED
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
INSULIN GLARGINE
Intervention (Drug)
Metformin
Intervention (Drug)
DPP-4 inhibitor
Intervention (Drug)
Sulphonylurea
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02027753
Content hash
592edb5fca2406571005cc4cdc7553d48a83d3f8a1ddb2a0db884b67b32b4f6e